RMOC briefing on adalimumab – October 2018

This fourth briefing paper is provided through the RMOC system. It forms the October edition of a series of briefings on best value biological medicines. The briefing summarises current aspects related to implementing best value biological medicines in the NHS.

AdalimumabBiosimilar medicineNewsRMOC medicines optimisation recommendations and resourcesRMOC recommendations and resources

Attachments